Form 8-K





Washington, DC 20549







Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2014



NanoString Technologies, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-35980   20-0094687

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)

530 Fairview Avenue North, Suite 2000

Seattle, Washington 98109

(Address of principal executive offices, including zip code)

(206) 378-6266

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 8.01 Other Events.

On August 6, 2014, NanoString Technologies, Inc. (the “Company”) was informed by Laboratory Corporation of America® Holdings (“LabCorp”) that UnitedHealthcare® has agreed to reimburse for testing services provided by LabCorp based on the Company’s Prosigna® Breast Cancer Gene Signature Assay (“Prosigna”). UnitedHealthcare will not require pre-authorization for Prosigna testing for any breast cancer patient meeting the Prosigna clinical criteria, as defined by the Prosigna package insert. UnitedHealthcare, one of the nation’s largest private healthcare insurance providers, is the first major commercial healthcare insurer to confirm coverage for Prosigna testing services.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


NanoString Technologies, Inc.

/s/ James A. Johnson

  James A. Johnson
  Chief Financial Officer

Date: August 7, 2014